ProMIS Neurosciences' Losses Mount Amid Soaring R&D Costs

Ticker: PMN · Form: 10-Q · Filed: 2025-08-13T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Neurodegenerative Diseases, Cash Burn, Going Concern, R&D Expenses, Liquidity Risk, Clinical Trials

Related Tickers: PMN

TL;DR

**PMN is burning cash at an alarming rate on R&D, and while recent financing offers a temporary reprieve, the long-term outlook remains highly speculative without a clear path to revenue.**

AI Summary

ProMIS Neurosciences Inc. (PMN) reported a significant increase in net loss for the three and six months ended June 30, 2025, reaching $10.1 million and $17.5 million, respectively, compared to $2.6 million and $6.3 million for the same periods in 2024. This substantial increase in loss was primarily driven by a surge in research and development (R&D) expenses, which escalated to $8.7 million for the three months ended June 30, 2025, from $1.6 million in the prior year, and to $14.2 million for the six months ended June 30, 2025, from $3.7 million. The company's cash balance significantly decreased from $13.3 million at December 31, 2024, to $4.5 million at June 30, 2025, with negative cash flows from operations of $8.8 million for the six months ended June 30, 2025. Total current assets nearly halved to $9.5 million from $18.9 million, while total current liabilities more than quadrupled to $9.8 million from $2.2 million. The company's accumulated deficit grew to $108.2 million as of June 30, 2025. Despite these financial challenges, ProMIS received gross proceeds of $21.6 million in July 2025 from warrant exercises and private placements, which management believes will help address liquidity concerns, though transaction costs are still being determined.

Why It Matters

ProMIS Neurosciences' escalating net losses and dwindling cash reserves, despite a recent $21.6 million capital injection, signal significant financial instability for investors. The substantial increase in R&D spending, while crucial for advancing its neurodegenerative disease pipeline (PMN310, PMN267, PMN442), has yet to yield revenue, placing immense pressure on future financing. For employees, this raises concerns about job security and the long-term viability of projects. Customers and the broader market, particularly those affected by Alzheimer's, ALS, and Parkinson's, face uncertainty regarding the timely development and availability of these potentially life-changing therapies, especially given the competitive landscape where larger pharmaceutical companies also vie for breakthroughs.

Risk Assessment

Risk Level: high — The company reported a net loss of $17.5 million for the six months ended June 30, 2025, and an accumulated deficit of $108.2 million, indicating a severe lack of profitability. Cash decreased from $13.3 million to $4.5 million, and negative cash flow from operations was $8.8 million, leading management to state that these conditions raise "substantial doubt about the Company's ability to continue as a going concern within the next twelve months."

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the significant cash burn and going concern warning, potential investors should wait for clear evidence of successful clinical trials and a more stable financial position before considering an investment.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
$9.51M
total Debt
$9.89M
net Income
-$17.46M
eps
-$0.50
gross Margin
N/A
cash Position
$4.51M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

Why did ProMIS Neurosciences' net loss increase so significantly in Q2 2025?

ProMIS Neurosciences' net loss increased significantly due to a substantial rise in research and development (R&D) expenses. For the three months ended June 30, 2025, R&D expenses were $8,749,784, a 444% increase from $1,625,821 in the same period of 2024.

What is ProMIS Neurosciences' current cash position and how has it changed?

As of June 30, 2025, ProMIS Neurosciences had $4,510,119 in cash. This represents a significant decrease from $13,291,167 at December 31, 2024, indicating a 66% reduction in cash over six months.

Does ProMIS Neurosciences have enough funding to continue operations?

Management believes that conditions raise "substantial doubt about the Company's ability to continue as a going concern within the next twelve months." While the company received $21.6 million in gross proceeds in July 2025, it will require additional funding for future clinical activities.

What are ProMIS Neurosciences' lead product candidates?

ProMIS Neurosciences' lead product candidates are PMN310 for Alzheimer's disease, PMN267 for ALS, and PMN442 for synucleinopathies like MSA and Parkinson's disease. These candidates target misfolded toxic proteins.

How much did ProMIS Neurosciences spend on R&D for the first six months of 2025?

For the six months ended June 30, 2025, ProMIS Neurosciences spent $14,214,034 on research and development. This is a significant increase compared to $3,749,599 for the same period in 2024.

What is ProMIS Neurosciences' accumulated deficit as of June 30, 2025?

As of June 30, 2025, ProMIS Neurosciences' accumulated deficit was $108,152,005. This reflects the cumulative losses incurred by the company since its inception.

What was the impact of financing activities on ProMIS Neurosciences' cash flow?

For the six months ended June 30, 2025, ProMIS Neurosciences had no net cash provided by financing activities. In contrast, for the same period in 2024, it received $190,274 from the issuance of Common Shares from an ATM Offering.

What is the primary focus of ProMIS Neurosciences' technology platform?

The primary focus of ProMIS Neurosciences' technology platform is to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody-based therapies for neurodegenerative diseases and other protein-misfolding diseases, specifically targeting misfolded toxic proteins.

How many Common Shares did ProMIS Neurosciences have outstanding as of August 13, 2025?

As of August 13, 2025, ProMIS Neurosciences had 51,806,497 Common Shares outstanding. This figure is higher than the 32,689,190 shares outstanding as of June 30, 2025, suggesting recent share issuances.

What is the significance of the $21.6 million received by ProMIS Neurosciences in July 2025?

The $21.6 million in gross proceeds received in July 2025 from discounted warrant exercises, private placements, and pre-funded warrants is significant because it provides a crucial, albeit temporary, infusion of capital to address the company's immediate liquidity concerns and support ongoing operations.

Risk Factors

Industry Context

ProMIS Neurosciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing therapeutics for neurodegenerative diseases. The industry is characterized by long development cycles, high failure rates, and significant R&D investment. Success often hinges on groundbreaking scientific discovery, robust clinical trial data, and securing substantial funding for preclinical and clinical development.

Regulatory Implications

As a biotechnology company, ProMIS is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet regulatory endpoints, or issues with manufacturing can significantly impact development timelines and costs. The company must navigate complex approval processes, which require extensive documentation and adherence to Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP).

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated Deficit
The cumulative net losses of a company that have not been offset by net income. It represents the total loss incurred by the company since its inception. (Indicates the company's long-term profitability and its reliance on external funding to cover ongoing losses, which stood at $108.2 million as of June 30, 2025.)
Current Assets
Assets that are expected to be converted to cash or consumed within one year or the operating cycle, whichever is longer. (ProMIS's current assets significantly decreased to $9.5 million as of June 30, 2025, from $18.9 million at the end of 2024, highlighting a deteriorating short-term financial position.)
Current Liabilities
Obligations that are due within one year or the operating cycle, whichever is longer. (ProMIS's current liabilities surged to $9.8 million as of June 30, 2025, from $2.2 million at the end of 2024, indicating an increased short-term financial burden.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. (These expenses for ProMIS increased dramatically to $8.7 million in Q2 2025 and $14.2 million year-to-date, driving the overall net loss.)
Net Loss
The total expenses of a company exceed its total revenues over a specific period. (ProMIS reported a significant increase in net loss, reaching $10.1 million for Q2 2025 and $17.5 million year-to-date, underscoring its current financial performance.)
Cash Burn
The rate at which a company is spending its available cash reserves, typically used for companies that are not yet profitable. (ProMIS experienced negative cash flows from operations of $8.8 million for the first six months of 2025, indicating a substantial cash burn.)

Year-Over-Year Comparison

Compared to the prior year, ProMIS Neurosciences has experienced a dramatic increase in its net loss, with Q2 2025 losses ($10.1M) being nearly four times larger than Q2 2024 ($2.6M). This is largely attributable to a surge in R&D expenses, which grew by 444% year-over-year. The company's financial health has also deteriorated significantly, evidenced by a 66% decrease in cash reserves and a more than quadrupling of current liabilities, leading to a negative working capital position. New risks related to the company's ability to manage its escalating expenses and maintain liquidity are now more pronounced.

Filing Stats: 4,316 words · 17 min read · ~14 pages · Grade level 19.3 · Accepted 2025-08-13 07:10:29

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II OTHER INFORMATION 32 Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

Signatures

Signatures 36 Table of Contents DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains statements that we believe are, or may be considered to be, "forward-looking statements." Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions of the Company. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as "plans," "expects" or "does not expect," "is expected," "look forward to," "budget," "scheduled," "estimates," "forecasts," "will continue," "intends," "the intent of," "have the potential," "anticipates," "does not anticipate," "believes," "should," "should not," or variations of such words and phrases that indicate that certain actions, events or results "may," "could," "would," "might," or "will," "be taken," "occur," or "be achieved," or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (" SEC ") or press releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially fr

Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to

Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to: the anticipated amount, timing and accounting of contingent, milestone, royalty and other payments under licensing or collaboration agreements; tax positions and contingencies; research and development costs; compensation and other selling, general and administrative expense; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; the potential impact of increased competition in the markets in which we compete; patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; our plans and investments in our portfolio as well as implementation of our corporate strategy; the risk that we will maintain enough liquidity to execute our business plan and our ability to continue as a going concern; our expected use of proceeds from sales of our common shares or common share equivalents in offerings or "at-the-market" offerings and the period over which such proceeds, together with existing cash, will be sufficient to meet our operating needs; our efforts to maintain our listing on Nasdaq; the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions; the expectations, development plans and anticipated timelines, including costs and timing of clinical trials, filings and approvals, of our products candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators' pipeline product candidates, if approved; the timing, outcome and impact of administrative, regulatory, legal and

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PROMIS NEUROSCIENCES INC. Condensed Consolidated Balance Sheets (expressed in US dollars, except share amounts) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash $ 4,510,119 $ 13,291,167 Short-term investments 33,051 33,051 Prepaid expenses and other current assets 4,966,326 5,587,238 Total current assets 9,509,496 18,911,456 Total assets $ 9,509,496 $ 18,911,456 Liabilities and Shareholders' (Deficit) Equity Current liabilities: Accounts payable $ 2,780,179 $ 1,737,463 Accrued liabilities 7,043,908 480,962 Total current liabilities 9,824,087 2,218,425 Share-based compensation liability 62,395 199,263 Warrant liability 5,592 5,592 Total liabilities 9,892,074 2,423,280 Commitments and contingencies Shareholders' (deficit) equity: Common Shares, no par value, unlimited shares authorized, 32,689,190 shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Additional paid-in capital 108,140,611 107,546,433 Accumulated other comprehensive loss ( 371,184 ) ( 371,184 ) Accumulated deficit ( 108,152,005 ) ( 90,687,073 ) Total shareholders' (deficit) equity ( 382,578 ) 16,488,176 Total liabilities and shareholders' (deficit) equity $ 9,509,496 $ 18,911,456 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents PROMIS NEUROSCIENCES INC. Condensed Consolidated Statements of Operations (expressed in US dollars, except share amounts) (Unaudited) For the For the For the For the Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 8,749,784 $ 1,625,821 $ 14,214,034 $ 3,749,599 General and administrative 1,434,877 1,087,885 3,430,723 2,640,758

View on Read The Filing